FDA Reverses Course, Clears Path for Outlook Therapeutics' LYTENAVA Resubmission

Event summary

  • FDA granted Outlook Therapeutics' appeal following Formal Dispute Resolution (FDR) process for LYTENAVA (bevacizumab-vikg).
  • FDA concluded substantial evidence of effectiveness for LYTENAVA in treating neovascular age-related macular degeneration (nAMD).
  • Outlook Therapeutics expects to resubmit the Biologics License Application (BLA) in June 2026 with a PDUFA decision expected within 60 days.
  • LYTENAVA is already approved in the EU and UK for wet AMD but remains investigational in the U.S.

The big picture

The FDA's reversal marks a significant shift in Outlook Therapeutics' regulatory trajectory, clearing a path for potential U.S. approval of LYTENAVA. This decision underscores the growing emphasis on robust clinical evidence in ophthalmology, particularly for treatments targeting nAMD, a condition with significant unmet needs. The approval, if granted, would position LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab, potentially reshaping the competitive landscape in retinal disease treatments.

What we're watching

Regulatory Execution
Whether Outlook Therapeutics can successfully navigate final labeling negotiations with the FDA and meet the June 2026 resubmission timeline.
Market Differentiation
How LYTENAVA will position itself against existing treatments for nAMD if approved, given its FDA-approved manufacturing process and labeling.
Commercialization Strategy
The pace at which Outlook Therapeutics can scale commercial operations in the U.S., following its existing launches in Europe.